Abstract
The mechanism by which non-steroidal anti-inflammatory drugs (NSAID), such as aspirin and indomethacin, provide symptomatic relief for patients with inflammatory disease is generally recognised to be by inhibition of the formation of prostaglandins (PG’s) from arachidonic acid (AA). The evidence for the involvement of PG’s in inflammation is that elevated levels of PG’s have been detected in inflamed tissues and that PG’s, particularly PGE2, have properties which suggest that they could mediate oedema, erythema and hyperalgesia. In addition, therapeutic doses of NSAID reduce the concentrations of PG’s in inflamed tissues (for review see 1).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
R.J. Flower, S. Moncada and J.R. Vane, Analgesic-antipyretics and anti-inflammatory agents: Drugs employed in the treatment of gout. In: Pharmacological Basis of Therapeutics Ed. A.G. Gilman, L.S. Goodman and A. Gilman, 682–728 (1980).
G.A. Higgs, K.E. Muggeridge, S. Moncada and J.R. Vane, The effects of non-steroid anti-inflammatory drugs on leukocyte accumulation in carrageenin-induced inflammation. Eur. J. Pharmacol. 66: 81–86 (1980).
R.C. Haynes and F. Murad, Adrenocorticotrophic hormone; adrenocortical steroids and their synthetic analogues; inhibitors of adrenocortical steroid biosynthesis. In: Pharmacological Basis of Therapeutics. Ed. A.G. Gilman, L.S. Goodman and A. Gilman, 1466–1496 (1980).
H. Kunze and W. Vogt, Significance of phospholipase A for prostaglandin formation. Ann. N.Y. Acad. Sci. 180: 123–125 (1971).
H. Vonkeman and D.A. Van Dorp, The action of prostaglandin synthetase on 2-arachidonyl lecithin. Biochim. Biophys. Acta. 164: 430–432 (1968).
R.J. Flower, G.J. Blackwell, M. Di Rosa and L. Parente, Mechanism of steroid-induced inhibition of arachidonate oxygenation. In: Mechanisms of steroid action. Ed. Lewis G.P. and Ginsberg, M. MacMillan Press. 97–114 (1981).
B. Samuelsson, S. Hammarstrom, R.C. Murphy and P. Borgeat, Leukotrienes and slow reacting substance of anaphylaxis (SRS-A). Allergy. 35: 375–381 (1980).
E.J. Goetzl and F.F. Sun, Generation of unique mono-hydroxy- eicosatetraenoic acids from arachidonic acid by human neutrophils. J. Exp. Med. 150: 406–411 (1979).
J.T. O’Flaherty, M.J. Thomas, C.J. Lees and C.E. McCall, Neutrophil-aggregating activity of monohydroxy- eicosatetraenoic acids. Am. J. Pathol. 104: 55–62 (1981).
R.M.J. Palmer, R.J. Stepney, G.A. Higgs and K.E. Eakins, Chemokinetic activity of arachidonic acid lipoxygenase products on leukocytes from different species. Prostaglandins. 20: 411–418 (1980).
W.F. Stenson and C.W. Parker, Monohydroxy-eicosatetraenoic acids (HETEs) induce degranulation of human neutrophils. J. Immunol. 124: 2100–2104 (1980).
G.A. Higgs, J.A. Salmon and J.A. Spayne, The inflammatory effects of hydroperoxy and hydroxy-acid products of arachidonate lipoxygenase in rabbit skin. Br. J. Pharmacol. 74: 429–433 (1981).
P. Bhattacherjee, B. Hammond, J.A. Salmon, R.J. Stepney and K.E. Eakins, Chemotactic response to some arachidonic acid lipoxygenase products in the rabbit eye. Eur. J. Pharmacol. 73: 21–28 (1981).
M.A. Bray, Pharmacology and pathophysiological of leukotriene B4. Brit. Med. Bull. 39: 249–254 (1983).
C.V. Wedmore and T.J. Williams, Control of vascular permeability by polymorphonuclear leukocytes in inflammation. Nature (Lond). 289: 646–650 (1981).
M.A. Bray, F.M. Cunningham, A.W. Ford-Hutchinson and M.J.H. Smith, Leukotriene B4: a mediator of vascular permeability. Br. J. Pharmacol. 72: 483–486 (1981).
C.L. Malmsten, J. Palmblad, A.M. Uden, O. Radmark, L. Engstedt and B. Samuelsson, Leukotriene B4: a highly potent and stereospecific factor stimulating migration of polymorphonuclear leukocytes. Acta. Physiol. Scand. 110: 449–451 (1980).
I. Hafstrom, J. Palmblad, C.L. Malmsten, O. Radmark and B. Samuelsson, Leukotriene B4- a stereospecific stimulator for release of lysosomal enzymes from neutrophils. FEBS Lett. 130: 146–148 (1981).
A.W. Ford-Hutchinson, M.A. Bray, F.M. Cunningham, E.M. Davidson and M.J.H. Smith, Isomers of leukotriene B, possess different biological potencies. Prostaglandins. 21: 143 151 (1981).
A.W. Ford-Hutchinson, G. Brunet, P. Savard and S. Cliarleson, Leukotriene B4, polymorphonuclear leukocytes and inflammatory exudates in the rat. Prostaglandins. 28: 13–37 (1984).
D.W. Goldman and E.J. Goetzl, Specific binding of leukotriene B4 to receptors on ’ human polymorphonuclear leukocytes. J. Immunol. 129: 1600–1604 (1982).
R.A. Kreisle and C.W. Parker, Specific binding of leukotriene B to a receptor on human polymorphonuclear leukocytes. J. Exp. Med. 157: 628–641 (1983).
P.M. Simmons, J.A. Salmon and S. Moncada, The release of leukotriene B, during experimental inflammation. Biochem. Pharmacol. 3n 1353–1359 (1983).
L.B. Klickstein, J. Shapleigh and E.J. Goetzl, Unique products of the oxygenation of arachidonic acid in synovial fluid in rheumatoid arthritis and spondylarthritis. Arth. Rheum. 23: 704–708 (1980).
S.A. Rae, E.M. Davidson and M.J.H. Smith, Leukotriene B(, an inflammatory mediator in gout. Lancet. 2: 1122–1123 (1982).
S.D. Brain, R.D.R. Camp, P.M. Dowd, A.K. Black, P.M. Woollard, A.I. Mallet and M.W. Greaves, Psoriasis and Leukotriene B4. Lancet. 2: 762 (1982).
J.A. Salmon, Bioassay and radioimmunoassay of eicosanoids. Brit. Med. Bull. 39: 227–231 (1983).
R.D.R. Camp, A.A. Coutts, M.W. Greaves, A.B. Kay and M.J. Walport, Responses of human skin to intradermal injections of leukotrienes C4, D4 and B4. Br. J. Pharmacol. 75: 168P (1982).
J. Bisgaard, J. Kristensen and J. Sondergaard, The effect of leukotriene C4 and D1 on cutaneous blood flow in humans. Prostaglandins. 23: 797–801 (1982).
S-E., Dahlen, J. Bjork, P. Hedqvist, K-E, Arfors, S. Hammarstrom, J.A. Lindgren and B. Samuelsson, Leukotrienes promote plasma leakage and leukocyte adhesion in post capillary venules: In vivo effects with reference to the acute inflammatory response. Proc. Natl. Acad. Sci. U.S.A. 78: 3887–3891 (1981).
A.W. Ford-Hutchinson and A. Rackman, Leukotrienes as mediators of skin inflammation. Brit. J. Dermatol. 109: 26–29 (1983).
G. Hansson and O. Radmark, Leukotriene C4: isolation from human polymorphonuclear leukocytes. FEBS Lett. 127: 87–90 (1980).
U. Aehringhaus, R.H. Wobling, W. Konig, C. Patrono, B.M. Peskar and B.A. Peskar, Release of leukotriene C4 from human polymorphonuclear leukocytes as determined by radioimmunoassay. FEBS Lett. 146: 111–114 (1982).
J.T. Zakrewski, N.C. Barnes, P.J. Piper and J.F. Coslello, Quantitation of leukotrienes in asthmatic sputum. Brit. J. Pharmacol. Proceedings of Dec. 1984 Meeting.
D.J. Masters and R.M. McMillan, 5-lipoxygenase from human leukocytes. Brit. J. Pharmacol. 81: 70P (1984).
R.W. Randall, K.E. Eakins, G.A. Higgs, J.A. Salmon and J.E. Tateson, Inhibition of arachidonic acid cyclooxygenase and lipoxygenase activities of leukocytes by indomethacin and compound BW755C. Agents and Actions. 10: 553–555 (1980).
J.A. Salmon, P.M. Simmons and R.M.J. Palmer, A radioimmunoassay for leukotriene B4. Prostaglandins. 24: 255–265 (1982).
M. Hamberg and B. Samuelsson, Prostaglandin endoperoxides. Novel transformations of arachidonic acid in human platelets. Proc. Natl. Acad. Sci. U.S.A. 71: 3400–3404 (1974).
G.M. Bokoch and P.M. Reed, Evidence for inhibition of leukotriene A[l 1 synthesis by 5,8,11,14-eicosatetraynoic acid in guinea pig polymorphonuclear leukocytes. J. Biol. Chem. 256, 4156–4159 (1981).
S. Hammarstrom, Selective inhibition of platelet n-8 lipoxygenase by 5,8,11-eicosatriynoic acid. Biochim. Biophys. Acta. 487: 517–519 (1977).
F.F. Sun, J.C. McGuire, D.R. Morton, J.E. Pike, H. Sprecher and W.H. Kuman, Inhibition of platelet arachidonic acid 12lipoxygenase by acetylenic acid compounds. Prostaglandins. 21: 333–343 (1981).
J.E. Wilhelm, S.K. Sankarappa, M. Van Rollins and H. Sprecher, Selective inhibitors of platelet lipoxygenase: 4,7,10,13icosatetraynoic acid and 5,8,11,14-henicosatetraynoic acid. Prostaglandins. 21: 323–332 (1981).
M. Hamberg, On the formation of thromboxane B and 12L-hydroxy 5,8,10,14-eicosatetraenoic acid (12-ho-20:47 in tissues from the guinea pig. Biochim. Biophys Acta. 431: 651–654 (1976).
J.Y. Vanderhoek, R.W. Bryant and J.M. Bailey, 15-hydroxy-5,8,11,13-eicosatetraenoic acid. A potent and selectiveinhibitor of platelet lipoxygenase. J. Biol. Chem. 255: 59965998 (1980).
J.Y. Vanderhoek, R.W. Bryant and J.M. Bailey, Inhibition of leukotriene biosynthesis by the leukocyte product 15-hydroxy5,8,11,13-eicosatetraenoic acid. J. Biol. Chem. 10064–10066 (1980).
E.A. Ham, D.D. Soderman, M.E. Zanetti, M.W., H.W. Dougherty, E. M.Cauley and F.A. Kuehl, Inhibition by prostaglandins of leukotriene B release from activated neutrophils. Proc. Natl. Acad. Sci. U.T.A. 80: 4349–4353 (1983).
H-E, Claesson, U. Lundberg and C. Malmsten, Serum-coated zymosan stimulates the synthesis of leukotriene B4 in human polymorphonuclear leukocytes. Inhibition by cyclic AMP. Biochem. Biophys. Res. Commun. 99: 1230–1237. (1981).
K. Sekiya and H. Okuda, Selective inhibition of platelet lipoxygenase by baicalein. Biochem. Biophys. Res Commun. 105: 1090–1095 (1982).
J. Baumann, F.V. Bruchhausen and G. Wurm, Flavonoids and related compounds as inhibitors of arachidonic acid peroxidation. Prostaglandins. 20: 627–639 (1980).
W.C. Hope, A.F. Welton, C. Fiedler-Nagy, C. Batula-Bernardo and J.W. Coffey, In vitro inhibition of the biosynthesis of slow reacting substance of anaphylaxis (SRS-A) and lipoxygenase activity by quercetin. Biochem. Pharmacol. 32: 367–371 (1983).
T. Neichi, Y. Koshihara and S. Murota, Inhibitory effect of esculetin on 5-lipoxygenase and leukotriene biosynthesis. Biochim. Biophys. Acta. 753: 130–132 (1983).
M.A. Bray, Retinoids are potent inhibitors of the generation of rat leukocyte leukotriene B -like activity in vitro. Eur. J. Pharmacol. 98: 61–67 (1984).
Y. Koshihara, T. Neichi, S. Murota, A. Lao, Y. Fujimoto and T. Tatsuno, Caffeic acid as a selective inhibitor for leukotriene biosynthesis. Biochim. Biophys. Acta. 792: 92–97 (1984).
G.A. Higgs, R.J. Flower and J.R. Vane, A new approach to anti- inflammatory drugs. Biochem. Pharmacol. 28: 1959–1961 (1979).
O. Radmark, C. Malmsten and B. Samuelsson, The inhibitory effects of BW755C on arachidonic acid metabolism in human polymorphonuclear leukocytes. FEBS Lett. 110: 213–215 (1980).
J.R. Walker and W. Dawson, Inhibition of rabbit PMN lipoxygenase activity by benoxaprofen. J. Pharm. Pharmacol. 31: 778–780 (1979).
J.A. Salmon, L.C. Tilling and S. Moncada, Benoxaprofen does not inhibit formation of leukotriene BCCi~ in a model of acute inflammation. Biochem. Pharmacol. L3: 2928–2930 (1984).
J.A. Salmon, L.C. Tilling and S. Moncade, Evaluation of inhibitors of eicosanoid synthesis in leukocytes: possible pitfall of using calcium ionophore A23187 to stimulate 5’-lipoxygenase. Sumbitted.
J.L. Humes, S. Sadowski, M. Galavage, M. Goldenberg, E. Subers, F.A. Kuehl and R. Bonney, Pharmacological effects of non-steroidal anti-inflammatory agents on prostaglandin and leukotriene synthesis in mouse peritoneal macrophages. Biochem. Pharmacol. 32: 2319–2322 (1983).
S. Fischer, M. Struppler and P.C. Weber, In vivo and in vitro effects of nafazatrom (BAY G 6576), an anti-thrombotic compound, on arachidonic acid metabolism in platelets and vascular tissue. Biochem. Pharmacol. 32: 2231–2236 (1983).
W.D. Busse, M. Mardin, R. Grutzmann, L.J. Marnett and T.E. Eling, Effect of nafazatrom and other lipoxygenase inhibitors on guaiacol peroxidation and arachidonic acid metabolism in microsomes and blood cells. V. Int. Conf. Prostaglandins Florence. p147 (1982).
Y. Koshihara, S. Murota, N. Petasis and K.C. Nicolaou, Selective inhibition of 5-lipoxygenase by 5,6-methano leukotriene Am a stable analogue of leukotriene A4. FEBS Lett. 143: 1Y - 16 (1982).
Y. Arai, M. Toda and M. Hayashi, Synthesis of (±)-carbanalogues of 5-HPETE and leukotrene A4. Adv. Prostaglandin,Thromboxane and Leukotriene Res. 11: 169–172 (1983).
E.J. Corey, J.R. Cashman, S.S. Kantner and S.W. Wright, Rationally designed potent competitive inhibitors of leukotriene biosynthesis. J. Am. Chem. Soc. 106: 1503–1504 (1984).
T. Yoshimoto, C. Yokoyama, K. Ochi, S. Yamamoto, Y. Maki, Y. Ashida, S. Terao and M. Shiraishi, 2,3,5-trimethyl-6-(12hydroxy-5, 10-dodecadinyl)-1,4-benzoquinone (AA 861), a selective inhibitor of the 5-lipoxygenase reaction and the biosynthesis • of slow reacting substance of anaphylaxis. Biochim. Biophys. Acta. 713: 470–473 (1982).
M.K. Bach, J.R. Brashler, H.W Smith, F.A. Fitzpatrick, F.F. Sun and J. C. McGuire, 6,9-deepoxy-6,9-(phenylimimo)- 6,8-prostaglandin I (U60257), a new inhibitor of leukotriene C and D synthesis: in vitro studies. Prostaglandins. 23: 759–771 (1982).
P. Needleman. A. Raz, M. Minkes, J.A. Ferrendelli and H. Sprecher, Triene prostanglandins:prostacyclin and thromboxane biosynthesis and unique biological properties. Proc. Natl. Acad. Sci. 76: 944–948 (1979).
D.A. Van Dorp, Aspects of the biosynthesis of prostaglandins. Progr. Biochem. Pharmacol. 3: 71–75 (1967).
B.A. Jakschik, A.R. Sams, H. Sprecher and P. Needleman, Fatty acid structural requirement for leukotriene biosynthesis. Prostaglandins. 23: 401–410 (1980).
R.C. Murphy, W.C. Pickett, B.R. Culp and W.E.M. Lands, Tetraene and pentaene leukotrienes: selective production from murine mastocytoma cells after dietary manipulation. Prostaglandins. 22: 613–622 (1981).
T. Terano, J.A. Salmon and S. Moncada, Biosynthesis and biological activity of leukotriene B5. Prostaglandins. 27: 217–232 (1984).
C. Yokoyama, K. Mizuno, H. Mitachi, T. Yoshimoto, S. Yamamotoand C.R. Pace-Asciak, Partial purification and characterisation of arachidonate 12-lipoxygenase from rat lung. Biochim. Biophys. Acta. 750: 237–241 (1983).
J.A. Salmon, A radioimmunoassay for 6-keto-PGFi. Prostaglandins. 15: 383–397 (1978).
J.A. Salmon, P.M. Simmons and S. Moncada, The effects of BW755C and other anti-inflammatory drugs on eicosanoid concentrations and leukocyte accumulation in experimentally-induced acute inflammation. J. Pharm. Pharmacol. 35: 808813 (1983).
J. Palmblad, A.M. Uden, J-A, Lindgren, O. Radmark, G. Hansson and C. Malmsten, Effects of novel leukotrienes on neutrophil migration. FEBS Lett. 144: 81–84 (1982).
R.D.R. Camp, P.M. Woollard. A.I. Mallet, N.J. Fincham, A.W. Ford- Hutchinson and M.A. Bray, Neutrophil aggregating and chemokinetic properties of a 5,12,20-trihydroxy-6,8,10,14eicostetraenoic acid isolated from human leukocytes. Prostaglandins. 23: 631–641 (1982).
R.M.J. Palmer and J.A. Salmon, Comparison of the effects of some compounds on human neutrophil degranulation and leukotriene B and thromboxane B2 Biochem. Pharmacol. In Press (1985). 2
T. Terano, J.A. Salmon and S. Moncada, Effect of orally administered eicosapentaenoic acid (EPA) on the formation of leukotriene B1. and leukotriene B5 by rat leukocytes. Biochem. Pharmacol. 3Y: 3071–3076 (1984).
T. Terano, J.A. Salmon, G.A. Higgs and S. Moncada, Anti- inflammatory activity of eicosapentaenoic acid. Submitted.
H.J. Showell, P.H. Naccache, R.I. Sha’afi and E.L. Becker, Inhibition of rabbit neutrophil lysosomal enzyme secretion, non-stimulated and chemotactic factor stimulated locomotion by nordihydroguaiaretic acid. Life Sci. 27: 421–426 (1980).
G.M. Bokoch and P.W. Reed, Inhibition of the neutrophil oxidative response to a chemotactic peptide by inhibitors of arachidonic acid oxygenation. Biochem. Biophys. Res. Commun. 90: 481487 (1979).
J.E. Smolen and G. Weissmann, Effects of indomethacin, 5,8,11.14eicosatetraynoic acid and p-bromophenacyl bromide on lysosomal enzyme release and superoxide anion generation by human polymorphonuclear leukocytes. Biochem. Pharmacol. 29: 533–538 (1980).
J.T. O’Flaherty, H.J. Showell, P.A. Ward and E.L. Becker, A possible role of arachidonic acid in human neutrophil aggregation and degranulation. Am. J. Pathol. 96: 799–809 (1979).
R.J. Smith, F.F. Sun, S.S. Iden, B.J. Bowman, H. Specher and J.C. McGuire, An evaluation of the relationship between arachidonic acid lipoxygenation and human neutrophil degranulation. Clin. Immunol. Immunophathol. 20: 157–169 (1981).
R.M.J. Palmer and J.A. Salmon, Stimulation of leukotriene B4 (LTB4) release from human neutrophils by N-formyl-Lmethionyl L-leucyl-L-phenylalanine (FMLP), serum-treated zymosan (STZ) and A23187 and its relationship to degranulation. Immunology. 50: 65–74 (1983).
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1985 Plenum Press, New York
About this chapter
Cite this chapter
Palmer, R.M.J., Salmon, J.A. (1985). Inhibition of 5’lipoxygenase: Relevance to Inflammation. In: Samuelsson, B., Berti, F., Folco, G.C., Velo, G.P. (eds) Drugs Affecting Leukotrienes and Other Eicosanoid Pathways. NATO ASI Series, vol 95. Springer, Boston, MA. https://doi.org/10.1007/978-1-4684-7841-9_24
Download citation
DOI: https://doi.org/10.1007/978-1-4684-7841-9_24
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4684-7843-3
Online ISBN: 978-1-4684-7841-9
eBook Packages: Springer Book Archive